OncoSil Medical Email Formats

Medical Equipment Manufacturing • Level 5, 7 Eden Park Drive Macquarie Park, Australia • 21-50 Employees

OncoSil Medical Email Formats

OncoSil Medical uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@oncosil.com), used 55% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@oncosil.com	55%
{first name}.{last name}	john.doe@oncosil.com	45%

Key Contacts at OncoSil Medical

Lel Smits

Non Executive Director

Caner Turay

Director Marketing, Oncosil Medical Ltd.

Raul Meza

Director Of Quality Assurance

Rachel Duggan

Director, Sales Emea

Daniel Kenny

Chief Executive Officer

Olaf Michaelsen

Director Access / Reimbursement / Economics / Assessment Emea

Nicole Gaddi

Director Of Regulatory Affairs

Henk Tissing

Director, Global Clinical Affairs

Company overview

Headquarters	Level 5, 7 Eden Park Drive Macquarie Park, Sydney, NSW 2113, AU
Phone number	+61289359629
Websites	oncosil.com oncosil.com.au
NAICS	3391
SIC	384
Keywords	Interventional Oncology
Employees	21-50
Socials

About OncoSil Medical

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy. OncoSil Medical’s lead product, OncoSil™, is a brachytherapy device which has received MDR approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹. We believe in our technology and its ability to have a truly positive impact in Oncology. OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications. Website link: oncosil.com References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.